Tonix Pharmaceuticals Plans to Expand TNX-102 SL Phase 3 Program Beyond PTSD to Include Fibromyalgia

Stock Information for Tonix Pharmaceuticals Holding Corp.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Tonix Pharmaceuticals Holding Corp.

Tonix Pharmaceuticals Announces Pricing of Public Offering of Common Stock
Tonix Pharmaceuticals Announces Issuance of Patent in China for the Composition and Formulation of TNX-102 SL
Tonix Pharmaceuticals Presented Results from Pharmacokinetic Analyses of TNX-102 SL in a Poster Presentation at the American Society of Clinical Psychopharmacology
Tonix Pharmaceuticals to Present at BIO 2019 International Convention
Tonix Pharmaceuticals Expands Pipeline with Mid-Stage Biologic Candidate TNX-1300 for Cocaine Intoxication
Tonix Pharmaceuticals to Speak at the Second Chance Digital Impact Recipient Gala
Tonix Pharmaceuticals Will Present Results from Pharmacokinetic Analyses of TNX-102 SL in a Poster Presentation at the American Society of Clinical Psychopharmacology
Tonix Pharmaceuticals Announces Director Stepping Down

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.